TY - JOUR AU - Einarson, T. R. AU - Acs, A. AU - Ludwig, C. AU - Panton, U. H. PY - 2018 DA - 2018// TI - Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 JO - Cardiovasc Diabetol. VL - 17 UR - https://doi.org/10.1186/s12933-018-0728-6 DO - 10.1186/s12933-018-0728-6 ID - Einarson2018 ER - TY - JOUR AU - Bays, H. E. AU - Jones, P. H. AU - Orringer, C. E. AU - Brown, W. V. AU - Jacobson, T. A. PY - 2016 DA - 2016// TI - National Lipid Association annual summary of clinical lipidology 2016 JO - J Clin Lipidol. VL - 10 UR - https://doi.org/10.1016/j.jacl.2015.08.002 DO - 10.1016/j.jacl.2015.08.002 ID - Bays2016 ER - TY - JOUR AU - Grundy, S. M. AU - Stone, N. J. AU - Bailey, A. L. PY - 2019 DA - 2019// TI - 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines JO - J Am Coll Cardiol VL - 73 UR - https://doi.org/10.1016/j.jacc.2018.11.002 DO - 10.1016/j.jacc.2018.11.002 ID - Grundy2019 ER - TY - JOUR AU - Mach, F. AU - Baigent, C. AU - Catapano, A. L. PY - 2019 DA - 2019// TI - ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk JO - Eur Heart J UR - https://doi.org/10.1093/eurheartj/ehz455 DO - 10.1093/eurheartj/ehz455 ID - Mach2019 ER - TY - JOUR AU - Verges, B. PY - 2015 DA - 2015// TI - Pathophysiology of diabetic dyslipidaemia: where are we? JO - Diabetologia VL - 58 UR - https://doi.org/10.1007/s00125-015-3525-8 DO - 10.1007/s00125-015-3525-8 ID - Verges2015 ER - TY - JOUR AU - Ryden, L. AU - Grant, P. J. AU - Anker, S. D. PY - 2013 DA - 2013// TI - ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) JO - Eur Heart J VL - 34 UR - https://doi.org/10.1093/eurheartj/eht108 DO - 10.1093/eurheartj/eht108 ID - Ryden2013 ER - TY - JOUR AU - Ference, B. A. AU - Kastelein, J. J. P. AU - Ray, K. K. PY - 2019 DA - 2019// TI - Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease JO - JAMA VL - 321 UR - https://doi.org/10.1001/jama.2018.20045 DO - 10.1001/jama.2018.20045 ID - Ference2019 ER - TY - JOUR AU - Robinson, J. G. AU - Wang, S. AU - Jacobson, T. A. PY - 2012 DA - 2012// TI - Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials JO - Am J Cardiol VL - 110 UR - https://doi.org/10.1016/j.amjcard.2012.07.007 DO - 10.1016/j.amjcard.2012.07.007 ID - Robinson2012 ER - TY - JOUR AU - Thanassoulis, G. AU - Williams, K. AU - Ye, K. PY - 2014 DA - 2014// TI - Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials JO - J Am Heart Assoc. VL - 3 UR - https://doi.org/10.1161/JAHA.113.000759 DO - 10.1161/JAHA.113.000759 ID - Thanassoulis2014 ER - TY - JOUR AU - Reiner, Z. AU - Catapano, A. L. PY - 2011 DA - 2011// TI - ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) JO - Eur Heart J VL - 32 UR - https://doi.org/10.1093/eurheartj/ehr158 DO - 10.1093/eurheartj/ehr158 ID - Reiner2011 ER - TY - JOUR AU - Mancini, G. B. AU - Hegele, R. A. AU - Leiter, L. A. PY - 2013 DA - 2013// TI - Dyslipidemia JO - Can J Diabetes. VL - 37 ID - Mancini2013 ER - TY - JOUR AU - Garber, A. J. AU - Abrahamson, M. J. AU - Barzilay, J. I. PY - 2019 DA - 2019// TI - Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary JO - Endocr Pract. VL - 25 UR - https://doi.org/10.4158/CS-2018-0535 DO - 10.4158/CS-2018-0535 ID - Garber2019 ER - TY - JOUR AU - Müller-Wieland, D. AU - Leiter, L. A. AU - Cariou, B. PY - 2017 DA - 2017// TI - Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk JO - Cardiovasc Diabetol. VL - 16 UR - https://doi.org/10.1186/s12933-017-0552-4 DO - 10.1186/s12933-017-0552-4 ID - Müller-Wieland2017 ER - TY - JOUR AU - Ray, K. K. AU - Leiter, L. A. AU - Muller-Wieland, D. PY - 2018 DA - 2018// TI - Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial JO - Diabetes Obes Metab VL - 20 UR - https://doi.org/10.1111/dom.13257 DO - 10.1111/dom.13257 ID - Ray2018 ER - TY - JOUR AU - Ginsberg, H. N. AU - Elam, M. B. PY - 2010 DA - 2010// TI - Effects of combination lipid therapy in type 2 diabetes mellitus JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa1001282 DO - 10.1056/NEJMoa1001282 ID - Ginsberg2010 ER - TY - JOUR AU - Scott, R. AU - O’Brien, R. AU - Fulcher, G. PY - 2009 DA - 2009// TI - Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study JO - Diabetes Care VL - 32 UR - https://doi.org/10.2337/dc08-1543 DO - 10.2337/dc08-1543 ID - Scott2009 ER - TY - JOUR AU - Bhatt, D. L. AU - Steg, P. G. AU - Miller, M. PY - 2019 DA - 2019// TI - Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1812792 DO - 10.1056/NEJMoa1812792 ID - Bhatt2019 ER - TY - JOUR AU - Catapano, A. L. AU - Graham, I. AU - Backer, G. PY - 2016 DA - 2016// TI - 2016 ESC/EAS guidelines for the management of dyslipidaemias JO - Eur Heart J VL - 37 UR - https://doi.org/10.1093/eurheartj/ehw272 DO - 10.1093/eurheartj/ehw272 ID - Catapano2016 ER - TY - JOUR AU - Fan, W. AU - Philip, S. AU - Granowitz, C. AU - Toth, P. P. AU - Wong, N. D. PY - 2019 DA - 2019// TI - Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey JO - J Clin Lipidol. VL - 13 UR - https://doi.org/10.1016/j.jacl.2018.11.008 DO - 10.1016/j.jacl.2018.11.008 ID - Fan2019 ER - TY - JOUR AU - Barter, P. AU - Gotto, A. M. AU - LaRosa, J. C. PY - 2007 DA - 2007// TI - HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa064278 DO - 10.1056/NEJMoa064278 ID - Barter2007 ER - TY - JOUR AU - Vallejo-Vaz, A. J. AU - Fayyad, R. AU - Boekholdt, S. M. PY - 2018 DA - 2018// TI - Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial JO - Circulation VL - 138 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.032318 DO - 10.1161/CIRCULATIONAHA.117.032318 ID - Vallejo-Vaz2018 ER - TY - JOUR AU - Nicholls, S. J. AU - Lincoff, A. M. AU - Bash, D. PY - 2018 DA - 2018// TI - Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial JO - Clin Cardiol VL - 41 UR - https://doi.org/10.1002/clc.23055 DO - 10.1002/clc.23055 ID - Nicholls2018 ER - TY - JOUR AU - Pradhan, A. D. AU - Paynter, N. P. AU - Everett, B. M. PY - 2018 DA - 2018// TI - Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study JO - Am Heart J VL - 206 UR - https://doi.org/10.1016/j.ahj.2018.09.011 DO - 10.1016/j.ahj.2018.09.011 ID - Pradhan2018 ER - TY - JOUR AU - Rosenson, R. S. AU - Daviglus, M. L. AU - Handelsman, Y. PY - 2019 DA - 2019// TI - Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study JO - Diabetologia VL - 62 UR - https://doi.org/10.1007/s00125-019-4856-7 DO - 10.1007/s00125-019-4856-7 ID - Rosenson2019 ER - TY - JOUR AU - Leiter, L. A. AU - Cariou, B. AU - Muller-Wieland, D. PY - 2017 DA - 2017// TI - Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial JO - Diabetes Obes Metab VL - 19 UR - https://doi.org/10.1111/dom.13114 DO - 10.1111/dom.13114 ID - Leiter2017 ER - TY - JOUR AU - Dijk, W. AU - May, C. AU - Cariou, B. PY - 2018 DA - 2018// TI - Beyond LDL: what Role for PCSK9 in triglyceride-rich lipoprotein metabolism? JO - Trends Endocrinol Metab VL - 29 UR - https://doi.org/10.1016/j.tem.2018.03.013 DO - 10.1016/j.tem.2018.03.013 ID - Dijk2018 ER - TY - JOUR AU - Frick, M. H. AU - Elo, O. AU - Haapa, K. PY - 1987 DA - 1987// TI - Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease JO - N Engl J Med VL - 317 UR - https://doi.org/10.1056/NEJM198711123172001 DO - 10.1056/NEJM198711123172001 ID - Frick1987 ER - TY - JOUR AU - Bhatt, D. L. AU - Steg, P. G. AU - Brinton, E. A. PY - 2017 DA - 2017// TI - Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial JO - Clin Cardiol VL - 40 UR - https://doi.org/10.1002/clc.22692 DO - 10.1002/clc.22692 ID - Bhatt2017 ER - TY - JOUR AU - Bowman, L. AU - Mafham, M. PY - 2018 DA - 2018// TI - Effects of n-3 fatty acid supplements in diabetes mellitus JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1804989 DO - 10.1056/NEJMoa1804989 ID - Bowman2018 ER - TY - JOUR AU - Leiter, L. A. AU - Tinahones, F. J. AU - Karalis, D. G. PY - 2018 DA - 2018// TI - Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials JO - Diabet Med VL - 35 UR - https://doi.org/10.1111/dme.13817 DO - 10.1111/dme.13817 ID - Leiter2018 ER - TY - JOUR AU - Ray, K. K. AU - Colhoun, H. M. AU - Szarek, M. PY - 2019 DA - 2019// TI - Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial JO - Lancet Diabetes Endocrinol. VL - 7 UR - https://doi.org/10.1016/S2213-8587(19)30158-5 DO - 10.1016/S2213-8587(19)30158-5 ID - Ray2019 ER - TY - JOUR AU - Colhoun, H. M. AU - Ginsberg, H. N. AU - Robinson, J. G. PY - 2016 DA - 2016// TI - No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies JO - Eur Heart J VL - 37 UR - https://doi.org/10.1093/eurheartj/ehw292 DO - 10.1093/eurheartj/ehw292 ID - Colhoun2016 ER - TY - JOUR AU - Caselli, C. AU - Turco, S. AU - Ragusa, R. PY - 2019 DA - 2019// TI - Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina JO - Cardiovasc Diabetol VL - 18 UR - https://doi.org/10.1186/s12933-019-0949-3 DO - 10.1186/s12933-019-0949-3 ID - Caselli2019 ER - TY - JOUR AU - Tinahones, F. J. AU - Laufs, U. AU - Cariou, B. PY - 2019 DA - 2019// TI - Alirocumab efficacy and safety by body mass index: a pooled analysis from 10 Phase 3 ODYSSEY trials JO - Diabetes Metab. UR - https://doi.org/10.1016/j.diabet.2019.101120:101120 DO - 10.1016/j.diabet.2019.101120:101120 ID - Tinahones2019 ER - TY - JOUR AU - Henry, R. R. AU - Muller-Wieland, D. AU - Taub, P. R. PY - 2018 DA - 2018// TI - Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: pooled data from 10 phase 3 trials JO - Diabetes Obes Metab VL - 20 UR - https://doi.org/10.1111/dom.13273 DO - 10.1111/dom.13273 ID - Henry2018 ER - TY - JOUR AU - Leiter, L. A. AU - Muller-Wieland, D. AU - Baccara-Dinet, M. T. AU - Letierce, A. AU - Samuel, R. AU - Cariou, B. PY - 2018 DA - 2018// TI - Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials JO - Diabet Med VL - 35 UR - https://doi.org/10.1111/dme.13450 DO - 10.1111/dme.13450 ID - Leiter2018 ER - TY - JOUR AU - Schwartz, G. G. AU - Steg, P. G. AU - Szarek, M. PY - 2018 DA - 2018// TI - Alirocumab and cardiovascular outcomes after acute coronary syndrome JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1801174 DO - 10.1056/NEJMoa1801174 ID - Schwartz2018 ER -